<u>/N 09/634,207</u> <u>PATENT</u>

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2 4 2003 pplicant:

Dennis A. Carson et al.

Examiner: Tamthom N Truong

erial No.:

09/634,207

Group Art Unit: 1624

Filed:

August 9, 2000

Docket: 103.022US1

Title:

INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

#### TERMINAL DISCLAIMER

RECEIVED

Commissioner for Patents Washington, D.C. 20231

**TECH CENTER 1/600/2900** 

MAR 2 8 2003

I, William F. Prout, am the attorney of record for the above identified patent application as evidenced by the Power of Attorney filed in the present application on August 9, 2000. I am making this petition on behalf of The Regents of the University of California, the assignee of the present invention. As the attorney of record, I am empowered to act on behalf of the assignee and, in accordance with 37 C.F.R. § 1.321(b)(iv), to sign this terminal disclaimer.

### Certificate Under 37 C.F.R. §3.73(b)

Your petitioner, The Regents of the University of California, certifies that they are the owner of the entire right, title and interest in and to the above-identified patent application (Serial No. 09/634,207), to U.S. Patent Application Serial No. 09/360,020 and to U.S. Patent Application Serial No. 09/589,476. Your petitioner owns the entire right, title, and interest of these applications by nature of the assignments executed and filed for all of these applications. The assignment for U.S. Application Serial No. 09/360,020 was recorded on October 18, 1999 on Reel 010308, Frames 0786 - 0792, with the United States Patent and Trademark Office. The assignment for U.S. Application Serial No. 09/589,476 was recorded on October 6, 2000 on Reel 011160, Frame 0880, with the United States Patent and Trademark Office. The above-identified patent application (Serial No. 09/634,207) is a continuation-in-part of U.S. Application Serial No. 09/360,020. Application Serial No. 09/589,476 is also a continuation-in-part of U.S. Application Serial No. 09/360,020.

The undersigned representative of the assignee has reviewed the evidentiary documents of title and certifies that to the best of assignee's knowledge and belief, title is in the assignee, The Regents of the University of California, seeking to take the action set forth in this disclaimer.

03/26/2003 CCHAU1

00000065 09634207

02 FC:2814

55.00 OP

# 15 TERMINAL DISCLAIMER

Serial Number: 09/634,207 Filing Date: August 9, 2000

Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

Page 2 Dkt: 103.022US1

#### Terminal Disclaimer

Your petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified patent application, which would extend beyond the expiration date of the full statutory term, as presently shortened by any terminal disclaimers, of any patent which may issue from U.S. Application Serial No. 09/360,020. Petitioner hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to any patent which may issue from U.S. Application Serial No. 09/360,020 and the legal title of the above-identified application and any patent granted thereon remain common, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

Your petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified patent application, which would extend beyond the expiration date of the full statutory term, as presently shortened by any terminal disclaimers, of any patent which may issue from U.S. Application Serial No. 09/589,476. Petitioner hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to any patent which may issue from U.S. Application Serial No. 09/589,476 and the legal title of the above-identified application and any patent granted thereon remain common, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

## Limitations on the Disclaimer

Your petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent which may be granted on U.S. Application Serial No. 09/360,020 or U.S. Application Serial No. 09/589,476 in the event that either of them later expire for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled

TERMINAL DISCLAIMER

Serial Number: 09/634,207 Filing Date: August 9, 2000

Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

Page 3 Dkt: 103.022US1

by a reexamination certificate, or is otherwise terminated prior to the expiration date of its

statutory term as presently shortened by any terminal disclaimer, except for the separation of

legal title as stated hereinabove. Your petitioner does not disclaim any terminal part of any

patent granted on the above-identified application if no patent issues from U.S. Application

Serial No. 09/360,020 or from U.S. Application Serial No. 09/589,476.

Fee Status

A check in the amount of \$55.00, which is required under 37 C.F.R. §1.20(d) to file a statutory disclaimer, is enclosed herewith. The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6968

Date March 17, 2003

William F. Prout

Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this day of March, 2003.

Name

Signature